Safimaltib
B-Cell Chronic Lymphocytic Leukemia
Explore 67 assets in B-Cell Chronic Lymphocytic Leukemia →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Janssen Research & Development, LLC
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06788509CT.gov A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring | — | Enrolling By Invitation | — | — | — |
NCT04876092CT.gov A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL | — | Completed | — | — | — |
NCT03900598CT.gov A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Chronic Lymphocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Safimaltib (this asset) | Janssen Research & Development, LLC | P1 | CCC · 48 |
| Humax-Cd20 | Emory University | P4 | BBB |
| Fludarabine | Ohio State University Comprehensive Cancer Center | P4 | BBB |
| Acalabrutinib | Zulfa Omer | P4 | BBB |
| Rituximab | Zulfa Omer | P4 | BBB |
| Cyclophosphamide | Ohio State University Comprehensive Cancer Center | P4 | BBB |
| Cediranib | City of Hope Medical Center | P2 | BB |
| Obinutuzumab | Paolo Caimi, MD | P3 | BB |
| Ibrutinib | Janssen Research & Development, LLC | P4 | BB |
+42 more in the B-Cell Chronic Lymphocytic Leukemia cohort
Other indications for Safimaltib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Hodgkin Lymphoma | — | P1 | CCC · 50 |
| Acute Myeloid Leukemia | — | P1 | CC · 41 |
| Castration-Resistant Prostate Carcinoma | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Safimaltib in B-Cell Chronic Lymphocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/safimaltib-b-cell-chronic-lymphocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →